v3.25.1
Segment Information - General (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Net product sales, cost of product sales and gross profit by product    
Total revenues $ 794.4 $ 677.7
Cost of sales 92.5 72.9
Gross profit (loss) 701.9 604.8
Tyvaso DPI    
Net product sales, cost of product sales and gross profit by product    
Total revenues 302.5 227.5
Cost of sales 48.1 33.3
Gross profit (loss) 254.4 194.2
Nebulized Tyvaso    
Net product sales, cost of product sales and gross profit by product    
Total revenues 163.8 145.0
Cost of sales 8.5 8.9
Gross profit (loss) 155.3 136.1
Remodulin    
Net product sales, cost of product sales and gross profit by product    
Total revenues 138.2 128.0
Cost of sales 13.8 7.9
Gross profit (loss) 124.4 120.1
Orenitram    
Net product sales, cost of product sales and gross profit by product    
Total revenues 120.7 106.2
Cost of sales 8.3 9.2
Gross profit (loss) 112.4 97.0
Unituxin    
Net product sales, cost of product sales and gross profit by product    
Total revenues 58.2 58.4
Cost of sales 5.2 3.6
Gross profit (loss) 53.0 54.8
Adcirca    
Net product sales, cost of product sales and gross profit by product    
Total revenues 6.0 6.4
Cost of sales 2.6 2.6
Gross profit (loss) 3.4 3.8
Other    
Net product sales, cost of product sales and gross profit by product    
Total revenues 5.0 6.2
Cost of sales 6.0 7.4
Gross profit (loss) $ (1.0) $ (1.2)